Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly-sensitized adult ESRD patients: report of the NIH IG02 trial
Go back to Resources
Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly-sensitized adult ESRD patients: report of the NIH IG02 trial
Authors:
Secondary:
Pagination: